Entering text into the input field will update the search result below

Clovis Oncology climbs 34% as shareholders reject reverse stock split

Jul. 08, 2022 12:27 PM ETClovis Oncology, Inc. (CLVSQ)By: Dulan Lokuwithana, SA News Editor7 Comments

Stock market data with uptrend vector

sitox/E+ via Getty Images

  • Clovis Oncology (NASDAQ:CLVS), a biotech focused on anti-cancer agents, added more than 34% on Friday to reach the highest level since April after the company’s shareholders rejected a proposal to implement a reverse stock split.
  • Disclosing the

Recommended For You

Comments (7)

Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

interesting and unknown reasons for the stock price movement both intraday and trend from 65 cents to 2.60+

do investors truly believe a buyout is likely ? or is it shorts and day traders causing spikes and then down turns

no clinical trial or product related press releases, ok, no reverse split and that’s a plus
Shame it’s not moving on an actual business news … maybe because there aren’t any
Thank you shareholders! We made a good decision
Any hope of this not going bankrupt?
I almost bought the stock in the Summer of 2018 at a much higher price. What a fortunate decision.
Mo Money 2011 profile picture
Moving on up!
now its time for big pharma buyout!
Let’s hope the same thing happens with HEPA
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.